Compound reference
Clinical studies, product labels and experimental findings for 124 compounds.
For example: elamipretide, testosterone cypionate, semaglutide
Reference entries
View all 124Regulatory update
Elamipretide / Forzinity
FDA granted Forzinity (elamipretide) accelerated approval on September 19, 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Approval used knee-extensor strength as an intermediate endpoint and requires confirmation of clinical benefit. It does not approve research-market SS-31 products or performance and longevity uses.[1][2]
US product-specific approval; benefit outside the labeled population is not established.
About this reference
Each finding includes its supporting source, study context and limitations. Abstract-only reviews and experimental evidence are labeled. Gaps remain visible; the site does not provide personal treatment or combination advice.
Evidence and citation methods